Activity of gemcitabine in patients with non-small cell lung cancer: A multicentre, extended phase II study

Cancer: Principles and Practice of Oncology.

1991 • 8,402 citations

Manual for Staging of Cancer

1992 • 2,367 citations

WHO Handbook for Reporting Results of Cancer Treatment

1982 • 2,214 citations

Action of 2',2'-difluorodeoxycytidine on DNA synthesis.

1991 • 868 citations

[Cancer of the lung].

1954 • 861 citations

Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients.

1994 • 836 citations

A phase I clinical, plasma, and cellular pharmacology study of gemcitabine.

1991 • 755 citations

Evaluation of the antitumor activity of gemcitabine (2',2'-difluoro-2'-deoxycytidine).

1990 • 670 citations

Comparison of the cellular pharmacokinetics and toxicity of 2',2'-difluorodeoxycytidine and 1-beta-D-arabinofuranosylcytosine.

1988 • 509 citations

Phase II Study of Taxol in Patients With Untreated Advanced Non-Small-Cell Lung Cancer

1993 • 441 citations

A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer.

1992 • 438 citations

American Joint Committee on Cancer

2015 • 387 citations

Single-agent activity of weekly gemcitabine in advanced non-small-cell lung cancer: a phase II study.

1994 • 376 citations

Efficacy and safety profile of gemcitabine in non-small-cell lung cancer: a phase II study.

1994 • 364 citations

Phase II Study of Taxol, Merbarone, and Piroxantrone in Stage IV Non-Small-Cell Lung Cancer: The Eastern Cooperative Oncology Group Results

1993 • 346 citations

Phase II Study of Gemcitabine (2',2'-Difluorodeoxycytidine) in Previously Treated Ovarian Cancer Patients

1994 • 332 citations

A Phase II Study of Navelbine (Vinorelbine) in the Treatment of Non-Small-Cell Lung Cancer

1991 • 260 citations

Weekly gemcitabine in advanced bladder cancer: A preliminary report from a phase I study

1994 • 192 citations

Gemcitabine is an active new agent in previously untreated extensive small cell lung cancer (SCLC)

1994 • 144 citations

Preclinical in vivo activity of 2',2'-difluorodeoxycytidine (Gemcitabine) against human head and neck cancer.

1991 • 138 citations

2',2'-Difluorodeoxycytidine Metabolism and Mechanism of Action In Human Leukemia Cells

1989 • 81 citations

Phase II study of 10-ethyl-10-deaza-aminopterin in patients with stage III and IV non-small-cell lung cancer.

1988 • 79 citations

Difluorodeoxycytidine (dFdC) — gemcitabine: A phase I study

1992 • 75 citations

Evaluation of new anticancer agents against the MIA PaCa-2 and PANC-1 human pancreatic carcinoma xenografts.

1993 • 63 citations

Modulation of deoxycytidylate deaminase in intact human leukemia cells

1992 • 55 citations

Phase II study of high-dose epirubicin in non-small cell lung cancer

1990 • 35 citations

Phase II study of 10-ethyl-10-deaza-aminopterin (10-EdAM; CGP 30 694) for stage IIIB or IV non-small cell lung cancer

1990 • 34 citations

Phase II study of Edatrexate in stage III and IV non-small-cell lung cancer

1992 • 32 citations

A review of etoposide in patients with non-small-cell lung cancer (NSCLC)

1982 • 12 citations

A phase II study of etoposide and splitted doses of CDDP for the treatment of non small cell lung cancer

1986 • 1 citations